Based Roundtable event for oncologists in the Chicago area, Ruta Rao, MD, a breast medical oncologist at Rush University Medical Center, walked participants through the data behind sacituzumab ...
FDA breakthrough therapy designation for daraxonrasib + GnP aims to accelerate development for first-line metastatic PDAC ...
Jonathan Villena-Vargas, MD, explains how a rib-sparing robotic approach cuts post-thoracotomy pain and opioid use for ...
Drs Aditya Shreenivas and Razelle Kurzrock break down a 200,000-tumor real-world study on HER2 IHC, ERBB2 alterations, and ...
The FDA has approved aminolevulinic acid (ALA) hydrochloride topical gel, 10% (Ameluz), in combination with photodynamic ...
The FDA has approved Pixclara (floretyrosine F 18), the first FET-PET imaging agent for distinguishing recurrent glioma from treatment-related change. The FDA has approved floretyrosine F 18 (18F-FET; ...
Manojkumar Bupathi, MD, MS, discusses the changes that biomarker-based treatment brings to hormone-sensitive prostate cancer.
MSOs and physician networks streamline oncology practice operations, cut administrative burden, and preserve autonomy—helping ...
Zidesamtinib (Jideytro) demonstrated a high objective response rate (ORR) in patients with previously untreated ROS1-positive ...
The National Comprehensive Cancer Network (NCCN) has published updated data on generic cancer medication shortages in the US, ...
Ku explains how many bispecific antibodies can act as molecular bridges, binding a tumor-associated antigen such as ...
In this episode of The Moonlight Shift, Gina Mauro sits down with Herbert Lepor, MD, who serves as the Martin Spatz Chair of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results